MedTrace Logo

Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

NCT04707261 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1990

Last updated 2024-07-01

No results posted yet for this study

Summary

The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.

Conditions

Interventions

DRUG

Dapagliflozin

Participants will receive dapagliflozin 10 mg once daily

DRUG

Placebo

Participants will receive placebo 10 mg once daily

Sponsors & Collaborators

  • Second Xiangya Hospital of Central South University

    collaborator OTHER

  • ZhuZhou Central Hospital

    collaborator OTHER

  • Xiangtan Central Hospital

    lead OTHER

Principal Investigators

  • Jianping Zeng, Ph.D. · Xiangtan Central Hospital

  • Shenghua Zhou, Ph.D. · Second Xiangya Hospital of Central South University

  • Chengming Wang, Ph.D. · ZhuZhou Central Hospital

  • Fanghua Xu, M.D. · The First People's Hospital of Xiangtan City

  • Zhiqiang Cai, M.D. · Xiangtan People's Hospital

  • Chonglun Zhou, M.D. · Xiangxiang People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-06
Primary Completion
2025-05-05
Completion
2026-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04707261 on ClinicalTrials.gov